CoLucid Pharmaceuticals (CLCD) : Traders are bullish on CoLucid Pharmaceuticals (CLCD) as it has outperformed the S&P 500 by a wide margin of 259.81% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.45%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 21.65% in the last 1 week, and is up 257.88% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 45.46% and the 50-Day Moving Average is 141.56%.The 200 Day SMA reached 322.2%
CoLucid Pharmaceuticals (NASDAQ:CLCD): After opening at $34.99, the stock dipped to an intraday low of $33.25 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $39.05 and the buying power remained strong till the end. The stock closed at $38.15 for the day, a gain of 9.82% for the day session. The total traded volume was 768,567. The stocks close on the previous trading day was $38.15.
CoLucid Pharmaceuticals (CLCD) : The most positive equity analysts on CoLucid Pharmaceuticals (CLCD) expects the shares to touch $52, whereas, the least positive believes that the stock will trade at $30 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $37 with an expected fluctuation of $10.39 from the mean.
CoLucid Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company that develops a product candidate, Lasmiditan, for the treatment of central nervous system (CNS) disorders. The Company develops oral Lasmiditan for the acute treatment of migraine headaches in adults and intravenous Lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings. Its Lasmiditan is used for the acute treatment of migraine headaches in adults without the vasoconstrictor activity associated with previous generations of migraine therapies. The Company has completed seven clinical studies for Lasmiditan, including a TQTc study and a Phase IIb study treating a single migraine attack in around 391 patients.